On July 19, 2022, the CDC updated its COVID-19 vaccine recommendations, approving the Novavax vaccine for emergency use authorization for adults 18 years and older. Novavax is a two-dose, protein-based COVID-19 vaccine that is currently being used in more than 40 countries and has been authorized by the European Union and the World Health Organization.

Novavax will now be the fourth COVID-19 vaccine available in the U.S., in addition to Pfizer, Moderna, and Johnson & Johnson. As a protein-based vaccine, Novavax is another option for people who are allergic to one of the components in a mRNA or viral-vector vaccine. The vaccine is currently authorized as a primary series only, and not as a booster dose.

Regulators authorized the vaccine following an extensive review of clinical trials and safety and effectiveness data. At the time of the announcement, the CDC stated that the Novavax vaccine would be available in the coming weeks.

Updated July 20, 2022

Related FAQS